Due to acetylation induces a reduction in α-synuclein oligomerization and aggregation, and SIRT2 interacts with alpha-synuclein leading to its deacetylation [74, 75], SIRT2 inhibition has been proposed as a potential therapeutics against synucleinopathies [76, 77]. This evidence concerns the gene SNCA and synucleinopathy.